FCABS254F

Sigma-Aldrich

Milli-Mark® Anti-EGFR-FITC Antibody

Milli-Mark®, from rabbit

Synonyme(s):
Receptor tyrosine-protein kinase ErbB-1, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor, epidermal growth factor receptor (avian
eCl@ss:
32160702
NACRES:
NA.41

Source biologique

rabbit

Niveau de qualité

100

antibody product type

primary antibodies

Clone

polyclonal

species reactivity

human

manufacturer/tradename

Milli-Mark®

Application(s)

flow cytometry: suitable

Isotype

IgG

Conjugué

FITC conjugate

N° d'accession NCBI

N° d'accession UniProt

Expédié(e)(s) dans

wet ice

Description générale

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. EGFR is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer. EGFR exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα). Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer. In addition to forming homodimers after ligand binding, EGFR may pair with another member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a result, autophosphorylation of five tyrosine (Y) residues in the C-terminal domain of EGFR occurs.

Spécificité

Antibody recognizes human EGFR

Immunogène

Ovalbumin conjugated synthetic peptide corresponding to amino acids 1156-1186 of the processed mouse EGF receptor (EGFR) C-terminal domain (Accession number Q01279). The immunizing sequence shares 28/31 identity with the human EGF receptor sequence.

Application

Research Sub Category
Growth Factors & Receptors
Research Category
Signaling
Milli-Mark Anti-EGFR-FITC Antibody is an antibody against EGFR for use in FC.

Qualité

Evaluated by flow cytometry using A431 cells

Description de la cible

134 kDa Calculated

Forme physique

Purified rabbit polyclonal IgG conjugated to FITC in PBS with 0.1% sodium azide and 15 mg/mL BSA.
Protein A Purfied

Stockage et stabilité

Maintain refrigerated at 2-8°C protected from light in undiluted aliquots for up to 6 months from date of receipt

Remarque sur l'analyse

Control
A431 cells

Informations légales

MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK Allemagne

WGK 2

Flash Point(F)

Not applicable

Point d'éclair C

Not applicable

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique

Réseaux sociaux

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Recherche. Développement. Production

Nous sommes un des tout premiers fournisseurs du secteur mondial des Sciences de la vie proposant des solutions et des services pour la recherche, le développement et la production en biotechnologies, et le développement et la production de produits thérapeutiques pharmaceutiques.

© 2021 Merck KGaA, Darmstadt, Allemagne et/ou ses sociétés affiliées. Tous droits réservés.

La reproduction d'une quelconque partie du contenu de ce site est strictement interdite sans autorisation.